A Plus Biotechnology CoTPE:6918 -1.59%71 PB Ratio is 2.01 as of Jul. 08, 2026, which is 24% below its 10-year median of 2.65. GuruFocus rates TPE:6918 with a GF Score™ of 71/100 and a GF Value™ of NT$87.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 787 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks better than 50.7% on this metric.
A Plus Biotechnology Co Ltd stock PB Ratio (=1.99) is close to 2-year low of 1.98.
The historical rank and industry rank for A Plus Biotechnology Co's PB Ratio or its related term are showing as below:
TPE:6918'
s PB Ratio Range Over the Past 10 Years
Min: 1.63 Med: 2.65 Max: 3.99
Current: 2.01
During the past 7 years, A Plus Biotechnology Co's highest PB Ratio was 3.99. The lowest was 1.63. And the median was 2.65.
TPE:6918's PB Ratio is ranked better than 50.7% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.06
vs TPE:6918: 2.01
During the past 12 months, A Plus Biotechnology Co's average Book Value Per Share Growth Rate was 22.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.30% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of A Plus Biotechnology Co was 8.70% per year. The lowest was 2.80% per year. And the median was 4.60% per year.
Back to Basics: PB Ratio
A Plus Biotechnology Co (TPE:6918) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, A Plus Biotechnology Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
A Plus Biotechnology Co (TPE:6918) has a PB Ratio of 2.01 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on A Plus Biotechnology Co and its competitors. This is 24% below median its historical median of 2.65. Over the past decade, A Plus Biotechnology Co's PB Ratio has ranged from 1.63 to 3.99. According to the industry distribution chart, A Plus Biotechnology Co ranks #388 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 49.3%.
Is A Plus Biotechnology Co's PB Ratio too high?
A Plus Biotechnology Co's current PB Ratio of 2.01 is 24% below median its 10-year median of 2.65. Over the past 10 years, this metric has ranged from a low of 1.63 to a high of 3.99. The Medical Devices & Instruments industry median PB Ratio is 2.06. A Plus Biotechnology Co's value of 2.01 is 2.4% below this industry median. Based on the distribution chart, A Plus Biotechnology Co ranks #388 out of 787 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, A Plus Biotechnology Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #388 out of 787 companies for PB Ratio. This puts A Plus Biotechnology Co in the upper half of its industry. The industry median PB Ratio is 2.06. A Plus Biotechnology Co's value of 2.01 is 2.4% below this benchmark. Historically, A Plus Biotechnology Co's own PB Ratio has ranged from 1.63 to 3.99 over the past decade. While the company's 10-year median is 2.65 vs. the industry median of 2.06, A Plus Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.06, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current PB Ratio of 2.01 is 2.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current PB Ratio is 2.01, which is 24% below median its own 10-year median of 2.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.15, compared to a current price of NT$74.30 — trading 14.7% below its estimated fair value. The current PB Ratio is 2.01, which is 24% below median its 10-year median of 2.65 and 2.4% below the Medical Devices & Instruments industry median of 2.06. A Plus Biotechnology Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current PB Ratio is 2.01 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$74.30 is trading 14.7% below its estimated GF Value™ of NT$87.15.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
PB Ratio: 2.01 (24% below median its 10-year median of 2.65)
GF Value™: NT$87.15 vs. price of NT$74.30 (14.7% below fair value)
Industry Position: 2.4% below the Medical Devices & Instruments median (#388 of 787)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
71GF Score
Get the complete analysis for TPE:6918
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
